NCT02008942View on ClinicalTrials.gov

Pharmacodynamic Evaluation of PL2200 Versus Enteric-Coated Aspirin in Diabetic Patients

PHASE3CompletedINTERVENTIONAL
Enrollment

57

Participants

Timeline

Start Date

January 31, 2014

Primary Completion Date

April 30, 2014

Study Completion Date

April 30, 2014

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

PL2200 Aspirin Capsules

325 mg aspirin; once per day for 10 days

DRUG

Enteric-coated aspirin caplets

325 mg aspirin; once per day for 10 days

Trial Locations (3)

33143

Miami Research Associates, Miami

45227

Medpace Clinical Pharmacology, Cincinnati

66219

PRA Clinical Pharmacology Center, Lenexa

Sponsors

Lead Sponsor

PLx Pharma
All Listed Sponsors
lead

PLx Pharma

INDUSTRY